19
Mar

Eli Lilly is betting up to $690 million that a drug from Korea’s Hanmi Pharmaceutical can successfully treat an array of autoimmune diseases, licensing an early-stage candidate with ambitious plans for future trials.

…read more

Source: Lilly inks a $690M deal to get its hands on an autoimmune drug

    

0 No comments